Investor Relations

Press Releases

Date Title/Summary View
Toggle Summary Aastrom Biosciences to Present at Fifth Annual Rodman & Renshaw Techvest Healthcare Conference
Aastrom Biosciences to Present at Fifth Annual Rodman & Renshaw Techvest Healthcare Conference Ann Arbor, Michigan, October 17, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that its President and CEO, R. Douglas Armstrong, Ph.D., will present at the Fifth Annual Rodman &
View HTML
Toggle Summary Herbert S. Schwartz, M.D. Appointed to Aastrom Biosciences' Technology Review Board
Herbert S. Schwartz, M.D. Appointed to Aastrom Biosciences' Technology Review Board Ann Arbor, Michigan, October 14, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced the appointment of Herbert S. Schwartz, M.D. to its Technology Review Board (TRB). Dr.
View HTML
Toggle Summary Aastrom Biosciences Receives NIH Grant to Develop Stem Cell Treatment for Diabetic Circulation Disorders
-- Study Marks Aastrom's Entry into Vascular Regeneration Marketplace --
View HTML
Toggle Summary Aastrom Biosciences Receives NIH Grant for Dendritic Cell Vaccine Research
-- Study Expands Aastrom's Tumor Antigen Primed Vaccine Approach to Ovarian Cancer --
View HTML
Toggle Summary Aastrom Biosciences Receives FDA Approval to Initiate Multi-Center Clinical Trial for Bone Graft Product
-- IND Approval Key Milestone for Aastrom's Stem Cell Product Program for Tissue Generation --
View HTML
Toggle Summary Aastrom Biosciences, Inc. Reports Fourth Quarter Financial Results
Aastrom Biosciences, Inc. Reports Fourth Quarter Financial Results Ann Arbor, Michigan, August 26, 2003 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today financial results for the fourth quarter and fiscal year ended June 30, 2003. The Company also reported significant achievements
View HTML
Toggle Summary Aastrom Biosciences Completes CE Mark Requirements for Third Dendritic Cell Therapy Product
-- Expands Aastrom's Cell Production Products Business --
View HTML